Zobrazeno 1 - 10
of 759
pro vyhledávání: ''
Autor:
Vivian E, Saper, Michael J, Ombrello, Adriana H, Tremoulet, Gonzalo, Montero-Martin, Sampath, Prahalad, Scott, Canna, Chisato, Shimizu, Gail, Deutsch, Serena Y, Tan, Elaine F, Remmers, Dimitri, Monos, Timothy, Hahn, Omkar K, Phadke, Elaine, Cassidy, Ian, Ferguson, Vamsee, Mallajosyula, Jianpeng, Xu, Jaime S, Rosa Duque, Gilbert T, Chua, Debopam, Ghosh, Ann Marie, Szymanski, Danielle, Rubin, Jane C, Burns, Lu, Tian, Marcelo A, Fernandez-Vina, Elizabeth D, Mellins, Jill A, Hollenbach, Claudio, Len
Publikováno v:
Annals of the Rheumatic Diseases. 81:406-415
ObjectivesDrug reaction with eosinophilia and systemic symptoms (DRESS) is a severe, delayed hypersensitivity reaction (DHR). We observed DRESS to inhibitors of interleukin 1 (IL-1) or IL-6 in a small group of patients with Still’s disease with aty
Autor:
J Garg, Analia Alvarez, Elizabeth Zuta-Santillan, Paul Brunetta, Ana Malvar, Cary M. Looney, Brad H. Rovin, Thomas Schindler, Richard Furie, Matthew D Cascino, Imran Hassan, Gustavo Aroca, Hilda Fragoso-Loyo
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveRandomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell d
Autor:
Anja Strangfeld, Ana M. Rodrigues, Loreto Carmona, Ludovic Trefond, Charalampos Papagoras, Laure Gossec, N Roux, Kimme L. Hyrich, Saskia Lawson-Tovey, Bernd Raffeiner, Elsa F Mateus, Gözde Kübra Yardımcı, Pedro Machado, Xavier Mariette
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩
Lawson-Tovey, S, Hyrich, K L, Gossec, L, Strangfeld, A, Carmona, L, Raffeiner, B, Yardımcı, G K, Trefond, L, Roux, N, Rodrigues, A, Papagoras, C, Mateus, E F, Mariette, X & Machado, P M 2021, ' SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases ', Annals of the rheumatic diseases . https://doi.org/10.1136/annrheumdis-2021-221217
Annals of the Rheumatic Diseases, BMJ Publishing Group, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩
Annals of the Rheumatic Diseases, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩
Lawson-Tovey, S, Hyrich, K L, Gossec, L, Strangfeld, A, Carmona, L, Raffeiner, B, Yardımcı, G K, Trefond, L, Roux, N, Rodrigues, A, Papagoras, C, Mateus, E F, Mariette, X & Machado, P M 2021, ' SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases ', Annals of the rheumatic diseases . https://doi.org/10.1136/annrheumdis-2021-221217
Annals of the Rheumatic Diseases, BMJ Publishing Group, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩
Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are often treated with immunomodulatory or immunosuppressive medications; consequently, they have been excluded alongside other immunocompromised patients from late stages of S
Autor:
Michael Bonelli, Stephan Blüml, Philipp Hofer, Leonhard X. Heinz, Stefan Winkler, Daniela Sieghart, Josef S Smolen, Marianne Graninger, Daniel Aletaha, Karin Stiasny, Helmuth Haslacher, Helga Radner, Selma Tobudic, Maximilian Koblischke, Renate Thalhammer, Thomas Perkmann, Daniel Mrak, Judith H. Aberle
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesEvidence suggests that B cell-depleting therapy with rituximab (RTX) affects humoral immune response after vaccination. It remains unclear whether RTX-treated patients can develop a humoral and T-cell-mediated immune response against SARS-C
Autor:
María Laura Acosta Felquer, Luciano LoGiudice, Enrique R. Soriano, María Laura Galimberti, Luis Daniel Mazzuoccolo, Javier Rosa
Publikováno v:
Annals of the Rheumatic Diseases. 81:74-79
ObjectivesTo compare the incidence of psoriatic arthritis (PsA) in patients with psoriasis (PsO) according to different treatments for their skin: topics/no treatment, conventional disease-modifying antirheumatic drugs (DMARDs) (cDMARDs) or biologica
Publikováno v:
Annals of the Rheumatic Diseases. 80:1393-1399
BackgroundHepatitis B surface antigen (HBsAg) reverse seroconversion (RS) can happen in patients with rheumatoid arthritis (RA) with resolved hepatitis B (RHB) undergoing biological disease-modifying antirheumatic drugs (bDMARDs). But the incidence a
Autor:
Antonio Manzo, Silvia Balduzzi, Eleonora Mauric, Laura Bogliolo, Fausto Baldanti, Terenzj Luvaro, Bernardo D’onofrio, Daniele Lilleri, Serena Bugatti, Maria Immacolata Greco, Ludovico De Stefano, Michele di Lernia, Irene Cassaniti, Iolanda Mazzucchelli, Carlomaurizio Montecucco
Publikováno v:
Annals of the Rheumatic Diseases. 80:1635-1638
Strategies aimed at expediting immunisation campaigns against COVID-19 include providing single vaccine doses to individuals with previous exposure to SARS-CoV-2 and delaying second doses. While such approaches are effective at the population level,
Autor:
Johan Askling, Daniela Di Giuseppe, Tor Olofsson, Karin Bengtsson, Lennart T H Jacobsson, Bente Glintborg, Helena Forsblad-d'Elia, Ulf Lindström
Publikováno v:
Annals of the Rheumatic Diseases
Lindström, U, Bengtsson, K, Olofsson, T, Di Giuseppe, D, Glintborg, B, Forsblad-D'elia, H, Jacobsson, L T H & Askling, J 2021, ' Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care : Does the choice of biological therapy matter? ', Annals of the Rheumatic Diseases, vol. 80, no. 11, pp. 1445-1452 . https://doi.org/10.1136/annrheumdis-2021-220420
Lindström, U, Bengtsson, K, Olofsson, T, Di Giuseppe, D, Glintborg, B, Forsblad-D'elia, H, Jacobsson, L T H & Askling, J 2021, ' Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care : Does the choice of biological therapy matter? ', Annals of the Rheumatic Diseases, vol. 80, no. 11, pp. 1445-1452 . https://doi.org/10.1136/annrheumdis-2021-220420
BackgroundThe effect of interleukin 17-inhibitors on anterior uveitis (AU) in spondyloarthritis (SpA) is poorly understood. This study aimed to compare the risk of AU during treatment with secukinumab versus tumour necrosis factor inhibitors (TNFi).M
Autor:
Varun Dhir, Shefali Khanna Sharma, Amita Aggarwal, Siddharth Jain, Aastha Khullar, Bidyalaxmi Leishangthem, Supriya Maurya, Ranjan Gupta, Aman Sharma, Sanjay Jain, Shankar Naidu, Veena Dhawan
Publikováno v:
Annals of the Rheumatic Diseases. 80:1376-1384
ObjectivesThere are no head-to-head trials of different dose escalation strategies of methotrexate (MTX) in RA. We compared the efficacy, safety and tolerability of ‘usual’ (5 mg every 4 weeks) versus ‘fast’ (5 mg every 2 weeks) escalation of
Autor:
Julien H Djossou, Pierre-Marie Duret, Elodie Bauer, Jean Hugues Salmon, Jean Sibilia, Francis Berenbaum, Isabelle Chary-Valckenaere, Jérémy Fort, M. Geoffroy, Christelle Sordet, Alain Meyer, Emmanuel Chatelus, Cassandre Fabre, Massiva Bensalem, J. Walther, Laurent Messer, Renaud Felten, Martin Soubrier, Laurent Arnaud, Luc Pijnenburg, Marion Couderc, Jacques-Eric Gottenberg, Nicolas Meyer, Jérémie Sellam, Rose-Marie Javier, Nathanael Sedmak, A. Fan, Marina Rinagel, M. Ardizzone
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 2021, ⟨10.1136/annrheumdis-2021-220549⟩
Annals of the Rheumatic Diseases, 2021, ⟨10.1136/annrheumdis-2021-220549⟩
Dear Editor, A potential association between rituximab and more severe COVID-19 outcomes has been previously raised, based on case reports, retrospective studies and mostly declarative registries.1–4 To further investigate this association, we focu